460 related articles for article (PubMed ID: 30060856)
1. Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13-26-Year-Old Young Men After HPV Vaccine Introduction.
Chandler E; Ding L; Gorbach P; Franco EL; Brown DA; Widdice LE; Bernstein DI; Kahn JA
J Adolesc Health; 2018 Jul; 63(1):43-49. PubMed ID: 30060856
[TBL] [Abstract][Full Text] [Related]
2. Who's Not Protected in the Herd? Factors Associated with Vaccine-Type HPV in Unvaccinated Women.
Smith C; Ding L; Gorbach PM; Franco EL; Kahn JA
J Pediatr Adolesc Gynecol; 2018 Apr; 31(2):89-93. PubMed ID: 28943220
[TBL] [Abstract][Full Text] [Related]
3. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
[TBL] [Abstract][Full Text] [Related]
4. Distribution of Vaccine-Type Human Papillomavirus Does Not Differ by Race or Ethnicity Among Unvaccinated Young Women.
Whittemore D; Ding L; Widdice LE; Brown DA; Bernstein DI; Franco EL; Kahn JA
J Womens Health (Larchmt); 2016 Nov; 25(11):1153-1158. PubMed ID: 27754751
[TBL] [Abstract][Full Text] [Related]
5. Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction.
Widdice LE; Bernstein DI; Franco EL; Ding L; Brown DR; Ermel AC; Higgins L; Kahn JA
Vaccine; 2019 Oct; 37(45):6832-6841. PubMed ID: 31582269
[TBL] [Abstract][Full Text] [Related]
6. Risk of Oral Human Papillomavirus Infection Among Sexually Active Female Adolescents Receiving the Quadrivalent Vaccine.
Schlecht NF; Masika M; Diaz A; Nucci-Sack A; Salandy A; Pickering S; Strickler HD; Shankar V; Burk RD
JAMA Netw Open; 2019 Oct; 2(10):e1914031. PubMed ID: 31651968
[TBL] [Abstract][Full Text] [Related]
7. Partner-Level and Sexual Networking Factors Are Associated With Vaccine-Type and Nonvaccine-Type Human Papillomavirus Infection After Vaccine Introduction in Young Women.
Kahn J; Washington C; Ding L; Wyllie T; Rosen B; Gorbach P
Sex Transm Dis; 2022 Jun; 49(6):429-436. PubMed ID: 35093984
[TBL] [Abstract][Full Text] [Related]
8. Non-Vaccine-Type Human Papillomavirus Prevalence After Vaccine Introduction: No Evidence for Type Replacement but Evidence for Cross-Protection.
Saccucci M; Franco EL; Ding L; Bernstein DI; Brown D; Kahn JA
Sex Transm Dis; 2018 Apr; 45(4):260-265. PubMed ID: 29465705
[TBL] [Abstract][Full Text] [Related]
9. Incidence and Types of Human Papillomavirus Infections in Adolescent Girls and Young Women Immunized With the Human Papillomavirus Vaccine.
Schlecht NF; Diaz A; Nucci-Sack A; Shyhalla K; Shankar V; Guillot M; Hollman D; Strickler HD; Burk RD
JAMA Netw Open; 2021 Aug; 4(8):e2121893. PubMed ID: 34424304
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Genital Human Papillomavirus Infection and Human Papillomavirus Vaccination Rates Among US Adult Men: National Health and Nutrition Examination Survey (NHANES) 2013-2014.
Han JJ; Beltran TH; Song JW; Klaric J; Choi YS
JAMA Oncol; 2017 Jun; 3(6):810-816. PubMed ID: 28114440
[TBL] [Abstract][Full Text] [Related]
11. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
12. An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway.
Enerly E; Flingtorp R; Christiansen IK; Campbell S; Hansen M; Myklebust TÅ; Weiderpass E; Nygård M
PLoS One; 2019; 14(10):e0223612. PubMed ID: 31600341
[TBL] [Abstract][Full Text] [Related]
13. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
[TBL] [Abstract][Full Text] [Related]
14. Association between human papillomavirus vaccine status and sexually transmitted infection outcomes among females aged 18-35 with a history of sexual activity in the United States: A population survey-based cross-sectional analysis.
Closson K; Karim ME; Sadarangani M; Naus M; Ogilvie GS; Donken R
Vaccine; 2020 Dec; 38(52):8396-8404. PubMed ID: 33239227
[TBL] [Abstract][Full Text] [Related]
15. Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States.
Chaturvedi AK; Graubard BI; Broutian T; Pickard RKL; Tong ZY; Xiao W; Kahle L; Gillison ML
J Clin Oncol; 2018 Jan; 36(3):262-267. PubMed ID: 29182497
[TBL] [Abstract][Full Text] [Related]
16. Differences between vaccinated and unvaccinated women explain increase in non-vaccine-type human papillomavirus in unvaccinated women after vaccine introduction.
Ding L; Widdice LE; Kahn JA
Vaccine; 2017 Dec; 35(52):7217-7221. PubMed ID: 29169890
[TBL] [Abstract][Full Text] [Related]
17. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
[TBL] [Abstract][Full Text] [Related]
18. Oral human papillomavirus (HPV) infection in men who have sex with men: prevalence and lack of anogenital concordance.
King EM; Gilson R; Beddows S; Soldan K; Panwar K; Young C; Jit M; Edmunds WJ; Sonnenberg P
Sex Transm Infect; 2015 Jun; 91(4):284-6. PubMed ID: 25887283
[TBL] [Abstract][Full Text] [Related]
19. Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years).
Guo F; Hirth JM; Berenson AB
Hum Vaccin Immunother; 2015; 11(10):2337-44. PubMed ID: 26376014
[TBL] [Abstract][Full Text] [Related]
20. Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction.
Covert C; Ding L; Brown D; Franco EL; Bernstein DI; Kahn JA
Hum Vaccin Immunother; 2019; 15(7-8):1962-1969. PubMed ID: 30633598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
